用于癌症的杂环分子靶向药物与纳米药物：最新进展与挑战
Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges.
作者信息
Liu Junxia, Chao Tengfei, Liu Yingying, Gong Chen, Zhang Yinan, Xiong Huihua
机构信息
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200000, China.
出版信息
Pharmaceutics. 2023 Jun 10;15(6):1706. doi: 10.3390/pharmaceutics15061706.
Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer.
癌症是全球首要的公共卫生问题。目前，分子靶向治疗已成为癌症的主要治疗方法之一，具有高效性和安全性。医学界仍在努力研发高效、极具选择性且低毒性的抗癌药物。基于肿瘤治疗靶点分子结构的杂环支架被广泛应用于抗癌药物设计。此外，纳米技术的快速发展给医学带来了一场革命。许多纳米药物已将靶向癌症治疗提升到了一个新水平。在这篇综述中，我们重点介绍了癌症中的杂环分子靶向药物以及与杂环相关的纳米药物。
Zotero 插件